Contents
pdf Download PDF pdf Download XML
109 Views
23 Downloads
Share this article
Research Article | Volume 15 Issue 3 (None, 2022) | Pages 53 - 55
Melanoma and basal cell carcinoma in the hereditary leiomyomatosis and renal cell cancer syndrome. An expansion of the oncologic spectrum.
 ,
 ,
Under a Creative Commons license
Open Access
PMID : PMC5385265
Received
May 14, 2016
Published
Nov. 30, 2016
Abstract

Background:Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is an autosomal dominant syndrome due to mutation in fumarate hydratase. Patients with HLRCC frequently develop cutaneous and uterine leiomyomata and are at risk for renal cell carcinoma. Rarely, other malignancies have been reported.Main observations:We report the development of basal cell carcinoma and melanoma in two siblings with genetically-confirmed HLRCC.Conclusions:It is unclear whether the development of melanoma and basal cell carcinoma in our patients is due directly to their mutations in the gene encoding fumarate hydratase, or genetic susceptibility at another unrelated locus, or whether these are incidental lesions. However this observation has implications for careful and routine skin surveillance in patients with HLRCC for lesions other than cutaneous leiomyomata.

Keywords
Recommended Articles
Research Article
Impact of COVID-19 on Sexually Transmitted Infection Burden: A Cross-Sectional Study from a Tertiary Care Hospital in Gujarat
...
Published: 02/08/2025
Original Article
An analysis of Morphometric characteristics of Supratrochlear foramen of humerus
Published: 08/06/2025
Original Article
Outcomes of Plastic Surgical Reconstruction of Diabetic Foot Ulcers Following Systemic Optimization and Local Infection Control: A Prospective Study
...
Published: 08/06/2025
Research Article
Comparative Study of Oral Levamisole versus Oral Betamethasone in Vitiligo: A Prospective Analysis.
...
Published: 28/06/2025
© Copyright Spejalisci Dermatolodzy